A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma.

Saved in:
Bibliographic Details
Title: A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma.
Authors: Laks DR; Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience & Human Behavior, UCLA, Los Angeles, California., Oses-Prieto JA; Department of Pharmaceutical Chemistry, UCSF, San Francisco, California., Alvarado AG; Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience & Human Behavior, UCLA, Los Angeles, California., Nakashima J; Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience & Human Behavior, UCLA, Los Angeles, California., Chand S; Department of Pharmaceutical Chemistry, UCSF, San Francisco, California., Azzam DB; Department of Neuroscience, UCLA, Los Angeles, California., Gholkar AA; Chemistry, UCLA, Los Angeles, California., Sperry J; Department of Molecular and Medical Pharmacology, UCLA., Ludwig K; Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience & Human Behavior, UCLA, Los Angeles, California., Condro MC; Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience & Human Behavior, UCLA, Los Angeles, California., Nazarian S; Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience & Human Behavior, UCLA, Los Angeles, California., Cardenas A; Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience & Human Behavior, UCLA, Los Angeles, California., Shih MYS; Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience & Human Behavior, UCLA, Los Angeles, California., Damoiseaux R; Department of Molecular and Medical Pharmacology, UCLA., France B; Department of Molecular and Medical Pharmacology, UCLA., Orozco N; Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience & Human Behavior, UCLA, Los Angeles, California., Visnyei K; Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience & Human Behavior, UCLA, Los Angeles, California., Crisman TJ; Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience & Human Behavior, UCLA, Los Angeles, California., Gao F; Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience & Human Behavior, UCLA, Los Angeles, California., Torres JZ; Chemistry, UCLA, Los Angeles, California., Coppola G; Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience & Human Behavior, UCLA, Los Angeles, California.; Department of Neurology, UCLA, Los Angeles, California., Burlingame AL; Department of Pharmaceutical Chemistry, UCSF, San Francisco, California., Kornblum HI; Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience & Human Behavior, UCLA, Los Angeles, California.; Department of Molecular and Medical Pharmacology, UCLA.; Chemistry, UCLA, Los Angeles, California.
Source: Neuro-oncology [Neuro Oncol] 2018 May 18; Vol. 20 (6), pp. 764-775.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1523-5866
DOI:10.1093/neuonc/nox215